BIOTRONIK Neuro Acquires Spinal Cord Stimulation System from Soin Neuroscience

BIOTRONIK Neuro, a division of the global medical device leader BIOTRONIK, has acquired a portfolio of intellectual property related to spinal cord stimulation (SCS) from Soin Neuroscience for an undisclosed amount. The transaction, announced on July 15, 2026, enhances BIOTRONIK Neuro’s technology platform aimed at chronic pain management. Soin Neuroscience, based in Centerville, Ohio, will continue to operate independently following the acquisition, which focuses solely on the intellectual property associated with its spinal cord stimulation program.

This acquisition builds on a prior research collaboration between BIOTRONIK Neuro and Soin Neuroscience, initiated in December 2025. The partnership involved evaluating novel waveforms and personalized SCS tuning approaches on BIOTRONIK Neuro's Prospera SCS System. The newly acquired patents encompass a range of technologies in spinal cord stimulation waveform design, adaptive programming, and the integration of machine learning and artificial intelligence into neuromodulation therapy. This strategic move is expected to facilitate the development of a next-generation spinal cord stimulation program within BIOTRONIK Neuro’s expanding portfolio.

Soin Neuroscience was founded by Dr. Amol Soin, a pain management physician, and has established itself as an innovator in the field of chronic pain treatment. The company has developed a variety of patented technologies aimed at reducing opioid reliance through advanced neuromodulation techniques. The acquisition of Soin’s intellectual property by BIOTRONIK Neuro underscores the significance of the Dayton region as a growing hub for medical device innovation, particularly in the life sciences sector.

For BIOTRONIK Neuro, this acquisition represents a critical enhancement to its existing capabilities in spinal cord stimulation therapy. The integration of Soin Neuroscience's technologies aligns with the company’s long-term objective of delivering more personalized and effective treatment options for patients suffering from chronic pain. The addition of data-driven, adaptive stimulation technologies will complement BIOTRONIK Neuro’s current offerings, which are already designed for flexible programming and remote patient management.

This transaction reflects broader trends within the medical device sector, where companies are increasingly seeking to enhance their technology platforms through strategic acquisitions. As the demand for innovative pain management solutions continues to rise, the integration of advanced technologies such as machine learning and adaptive programming will likely play a pivotal role in shaping the future of neuromodulation therapies. The acquisition not only reinforces BIOTRONIK Neuro’s commitment to advancing neuromodulation science but also highlights the importance of collaboration and innovation within the medical technology landscape.